December 2014

New Product - Breo Ellipta

Breo Ellipta (fluticasone furoate/ vilanterol (as trifenatate)) contains a synthetic trifluorinated corticosteroid with potent anti inflammatory activity and a selective long-acting, beta₂-adrenergic agonist (LABA). Breo Ellipta is indicated in the symptomatic treatment of patients with COPD with a FEV₁ < 70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy. Breo Ellipta is also indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta₂-agonist. Breo Ellipta is contraindicated in patients with severe milk protein allergy. Breo Ellipta (100 mcg/25 mcg, 200 mcg/25 mcg) is available as a moulded plastic inhaler containing two strips of 30 regularly distributed blisters.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au